Viridian Therapeutics VRDN
$29.96 −$1.48 (-4.71%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $29.96 0.00%
Open$31.12
Prev close$31.44
Day range$29.87 – $31.75
Volume1.75M
Market cap$3.40B
P/E (TTM)–
Dividend yield–
VRDN Stock News
Headlines matching Viridian Therapeutics or the VRDN ticker, most recent first.
- RBC Capital Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $38 Positive
- Truist Financial Maintains Viridian Therapeutics(VRDN.US) With Buy Rating
- A Quick Look at Today's Ratings for Viridian Therapeutics(VRDN.US), With a Forecast Between $22 to $41
- Truist Financial Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $39 Positive
- Wedbush Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $43
- Goldman Sachs Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $40 Positive
- Stifel Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $40
- Truist Financial Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $39
- Evercore Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $26
- Wells Fargo Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $31
- Stifel Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $40 Positive
- A Quick Look at Today's Ratings for Viridian Therapeutics(VRDN.US), With a Forecast Between $22 to $43
- Jefferies Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $30 Positive
- Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN) and Fortrea Holdings Inc. (FTRE)
- A Quick Look at Today's Ratings for Viridian Therapeutics(VRDN.US), With a Forecast Between $22 to $35
No comments yet — be the first to weigh in on VRDN.
Sign in to join the discussion.